Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2026)

Akebia Therapeutics (AKBA) has 8 years of Asset Writedowns and Impairment data on file, last reported at $3.2 million in Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $3.2 million, up 1873.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 2645.21% YoY), and the FY2024 annual result was $294000.0, changed N/A from the prior year.
• Asset Writedowns and Impairment grew to $3.2 million in Q1 2026 per AKBA's latest filing, from $500000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $5.3 million in Q1 2022 and troughed at -$2.1 million in Q4 2024.
• A 5-year average of $1.0 million and a median of $500000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2023 and 2026: Asset Writedowns and Impairment plunged 85.71% in 2023, then soared 1873.01% in 2026.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $2.6 million in 2022, then sank by 151.04% to -$1.3 million in 2023, then slumped by 58.93% to -$2.1 million in 2024, then jumped by 123.71% to $500000.0 in 2025, then jumped by 543.2% to $3.2 million in 2026.
• Business Quant data shows AKBA's Asset Writedowns and Impairment at $3.2 million in Q1 2026, $500000.0 in Q3 2025, and $163000.0 in Q1 2025.